News | Heart Valve Technology | April 06, 2018

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

New APOLLO trial of Intrepid TMVR system offers alternative option for patients with severe mitral regurgitation

University Hospitals Performs Ohio's First Transcatheter Mitral Valve Replacement

April 6, 2018 —  University Hospitals Harrington Heart & Vascular Institute has officially opened the APOLLO trial, implanting the first Intrepid transcatheter mitral valve replacement system in the study. Alan Markowitz, M.D., and Guilherme F. Attizzani, M.D., performed the procedure, the first in the state of Ohio.

As part of the APOLLO trial, UH patients with severe symptomatic mitral regurgitation will have the opportunity to be randomized to receive either conventional open-heart mitral valve replacement surgery or an investigational transcatheter mitral valve replacement (TMVR). In addition, patients who are not good surgical candidates could have the opportunity of being treated with TMVR.

According to Attizzani, UH interventional cardiologist and co-director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, the APOLLO trial is a welcome development for patients with mitral valve disease.

“There is currently no TMVR technology approved by the FDA [U.S. Food and Drug Administration] and this trial may open a new, very important avenue on the field,” said Attizzani, who is also assistant professor of medicine at Case Western Reserve University School of Medicine. “The only percutaneous technologies we currently have to treat mitral insufficiency are MitraClip, which enables percutaneous native mitral valve repair, and transcatheter valves used for valve-in-valve procedures. This study is, therefore, extremely important as it may lead to a paradigm shift in terms of the treatment of native mitral valve insufficiency.”

The APOLLO trial is testing the Intrepid TMVR system, which is compressed inside a hollow delivery catheter and is inserted between the ribs to enter the heart. The new replacement valve is expanded directly into the malfunctioning mitral valve. The outer stent frame is designed to attach and conform to the native valve without the need for additional sutures, tethers or anchors to secure the prosthesis. The inner stent houses the valve, which is made from bovine tissue and is intended to maintain blood flow.

The Intrepid valve is implanted using a transapical approach through the apex. However, the technology is expected to evolve and become even less invasive.

“Today, surgeons need to open a small hole in the apex of the heart, then the valve is advanced through it and implanted,” said Markowitz, chief surgical officer, and director, Valve and Structural Heart Disease Center, UH Harrington Heart & Vascular Institute, and clinical assistant professor of surgery, CWRU School of Medicine. “It’s a beating-heart procedure without the heart-lung machine. Industry is, however, already working on a technology that is going to be transseptal (i.e., can be done via puncture of the femoral vein). This will further reduce the invasion to the patient by not having to go through the apex.”

UH is the only healthcare system in Northeast Ohio to give its patients access to the APOLLO trial.

“In addition to the APOLLO trial, we offer MitraClip therapy, an FDA-approved therapy for mitral valve insufficiency,” said Markowitz. “We also perform valve-in-valve and other complex procedures. It’s the full spectrum of mitral valve interventions, a combined effort of interventional cardiology and cardiac surgery.”

Once the APOLLO trial is completed, Attizzani expects patients with mitral valve disease to have more options to treat mitral valve disorders.

“Although it is impossible to predict the trial results, my expectation is that the TMVR system will be shown to be safe and effective,” said Attizzani. “If it is demonstrated to be non-inferior to surgical mitral valve replacement, it will be a key step in terms of the potential future approval of this novel technology by the FDA, ultimately enabling more patients to have the option of an effective and less invasive procedure.”

For more information: www.medtronic.com

 

Related Content

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient.

A CT scan assessment of the femoral access route challenges for a recent Central DuPage Hospital TAVR candidate. This image and the measurements were discussed by the heart team during its weekly meeting to determine if the TAVR delivery catheters could navigate the disease femoral artery and what options might best serve this patient. 

 

Feature | Heart Valve Technology | April 20, 2018 | Dave Fornell
While there is fear by many about the trend of hospitals consolidating into larger healthcare systems, one advantage
A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

A transcaval access TAVR procedure, showing a guide wire in the vena cava and a snare located in the aorta to pull the guide wire through.

Feature | Heart Valve Technology | April 19, 2018 | Dave Fornell
Patient selection for who is best suited for a ...
Videos | Heart Valve Technology | April 18, 2018
Northwestern Medicine has purchased several smaller Chicago suburban hospitals in the past few years to expand its he
LivaNova Announces Enrollment for PERFECT Perceval Valve Clinical Trial in China
News | Heart Valve Technology | March 30, 2018
LivaNova PLC announced the first patient enrollment in the Perceval Valve Clinical study for Chinese Registration (“...
Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
News | Heart Valve Technology | March 27, 2018
March 27, 2018 — Edwards Lifesciences Corp.
Videos | Heart Valve Technology | March 15, 2018
Insights from the STS/ACC TVT Transcatheter Valve Registry, presented at the American College of Cardiology (ACC) 201
CoreValve TAVR System Shows Strong Long-Term Performance in Clinical Trials
News | Heart Valve Technology | March 12, 2018
Medtronic plc unveiled outcomes from the CoreValve U.S. Pivotal Extreme Risk Study and the real-world NOTION trial (...
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used in newborn pediatric patients to treat heart defects.
News | Heart Valve Technology | March 07, 2018
The U.S. Food and Drug Administration expanded the approval of a heart valve to include a size small enough to be used...
Videos | Heart Valve Technology | March 02, 2018
Sammy Elmariah, M.D., MPH, interventional structural heart disease, Massachusetts General Hospital, discusses the pro
Boston Scientific Projects 2019 Launch for Lotus Edge Aortic Valve System
News | Heart Valve Technology | February 23, 2018
February 23, 2018 — Boston Scientific announced In November 2017 a delay to timelines for commercialization of the Lo
Overlay Init